Sinusoidal Obstruction Syndrome Following Myeloablative Therapy and Tranexamic Acid Treatment for Hemorrhage in Two Patients with Neuroblastoma.

Autor:	Zirngibl F; Department of Pediatric Hematology and Oncology, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.; Berliner Institut für Gesundheitsforschung (BIH), 10178 Berlin, Germany., Flemmig C; Department of Pediatric Hematology and Oncology, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.; Parexel International GmbH, 14050 Berlin, Germany., Lang P; Department of Pediatrics, Children's University Hospital, University of Tübingen, 72076 Tübingen, Germany., Künkele A; Department of Pediatric Hematology and Oncology, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.; Berliner Institut für Gesundheitsforschung (BIH), 10178 Berlin, Germany.; German Cancer Consortium (DKTK), Partner Site Berlin, 10117 Berlin, Germany., Eggert A; Department of Pediatric Hematology and Oncology, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.; Berliner Institut für Gesundheitsforschung (BIH), 10178 Berlin, Germany.; German Cancer Consortium (DKTK), Partner Site Berlin, 10117 Berlin, Germany.; German Cancer Research Center Heidelberg (DKFZ), 69120 Heidelberg, Germany., Schulte JH; Department of Pediatric Hematology and Oncology, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.; Berliner Institut für Gesundheitsforschung (BIH), 10178 Berlin, Germany.; German Cancer Consortium (DKTK), Partner Site Berlin, 10117 Berlin, Germany.; German Cancer Research Center Heidelberg (DKFZ), 69120 Heidelberg, Germany., Deubzer HE; Department of Pediatric Hematology and Oncology, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.; Berliner Institut für Gesundheitsforschung (BIH), 10178 Berlin, Germany.; German Cancer Consortium (DKTK), Partner Site Berlin, 10117 Berlin, Germany.; German Cancer Research Center Heidelberg (DKFZ), 69120 Heidelberg, Germany.; Experimental and Clinical Research Center (ECRC), Charité-Universitätsmedizin Berlin and the Max-Delbrueck-Center for Molecular Medicine (MDC) in the Helmholtz Association, 13125 Berlin, Germany.
Jazyk:	angličtina
Zdroj:	Children (Basel, Switzerland) [Children (Basel)] 2020 Oct 28; Vol. 7 (11). Date of Electronic Publication: 2020 Oct 28.
DOI:	10.3390/children7110198
Abstrakt:	Adverse thromboembolic events following administration of the anti-fibrinolytic agent tranexamic acid (TA), used to prevent/treat excessive blood loss, are rare. We present the clinical course of two young patients (22 and 56 months) receiving busulfan/melphalan (Bu/Mel) high-dose chemotherapy with autologous hematopoietic stem cell transplantation (HSCT) to treat high-risk neuroblastoma, who developed hepatic sinusoidal obstruction syndrome (SOS) within 48 h after systemic TA treatment for a hemodynamically relevant hemorrhage. Defibrotide treatment resolved hepatic SOS, but the short time between TA administration and SOS onset suggests a causal association.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu